Literature DB >> 26547931

Cancer Prevention: Obstacles, Challenges and the Road Ahead.

Frank L Meyskens1, Hasan Mukhtar2, Cheryl L Rock2, Jack Cuzick2, Thomas W Kensler2, Chung S Yang2, Scott D Ramsey2, Scott M Lippman2, David S Alberts2.   

Abstract

Approaches to reduce the global burden of cancer include two major strategies: screening and early detection and active preventive intervention. The latter is the topic of this Commentary and spans a broad range of activities. The genetic heterogeneity and complexity of advanced cancers strongly support the rationale for early interruption of the carcinogenic process and an enhanced focus on prevention as a priority strategy to reduce the burden of cancer; however, the focus of cancer prevention management should be on individuals at high risk and on primary localized disease in which screening and detection should also play a vital role. The timing and dose of (chemo-)preventive intervention also affects response. The intervention may be ineffective if the target population is very high risk or already presenting with preneoplastic lesions with cellular changes that cannot be reversed. The field needs to move beyond general concepts of carcinogenesis to targeted organ site prevention approaches in patients at high risk, as is currently being done for breast and colorectal cancers. Establishing the benefit of new cancer preventive interventions will take years and possibly decades, depending on the outcome being evaluated. We also propose that comparative effectiveness research designs and the value of information obtained from large-scale prevention studies are necessary in order for preventive interventions to become a routine part of cancer management.
© The Author 2015. Published by Oxford University Press. All rights reserved. For Permissions, please e-mail: journals.permissions@oup.com.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26547931      PMCID: PMC4907357          DOI: 10.1093/jnci/djv309

Source DB:  PubMed          Journal:  J Natl Cancer Inst        ISSN: 0027-8874            Impact factor:   13.506


  102 in total

Review 1.  The gut microbiota, bacterial metabolites and colorectal cancer.

Authors:  Petra Louis; Georgina L Hold; Harry J Flint
Journal:  Nat Rev Microbiol       Date:  2014-09-08       Impact factor: 60.633

Review 2.  Progress in chemoprevention drug development: the promise of molecular biomarkers for prevention of intraepithelial neoplasia and cancer--a plan to move forward.

Authors:  Gary J Kelloff; Scott M Lippman; Andrew J Dannenberg; Caroline C Sigman; Homer L Pearce; Brian J Reid; Eva Szabo; V Craig Jordan; Margaret R Spitz; Gordon B Mills; Vali A Papadimitrakopoulou; Reuben Lotan; Bharat B Aggarwal; Robert S Bresalier; Jeri Kim; Banu Arun; Karen H Lu; Melanie E Thomas; Helen E Rhodes; Molly A Brewer; Michele Follen; Dong M Shin; Howard L Parnes; Jill M Siegfried; Alison A Evans; William J Blot; Wong-Ho Chow; Patricia L Blount; Carlo C Maley; Kenneth K Wang; Stephen Lam; J Jack Lee; Steven M Dubinett; Paul F Engstrom; Frank L Meyskens; Joyce O'Shaughnessy; Ernest T Hawk; Bernard Levin; William G Nelson; Waun Ki Hong
Journal:  Clin Cancer Res       Date:  2006-06-15       Impact factor: 12.531

3.  A risk prediction algorithm based on family history and common genetic variants: application to prostate cancer with potential clinical impact.

Authors:  Robert J Macinnis; Antonis C Antoniou; Rosalind A Eeles; Gianluca Severi; Ali Amin Al Olama; Lesley McGuffog; Zsofia Kote-Jarai; Michelle Guy; Lynne T O'Brien; Amanda L Hall; Rosemary A Wilkinson; Emma Sawyer; Audrey T Ardern-Jones; David P Dearnaley; Alan Horwich; Vincent S Khoo; Christopher C Parker; Robert A Huddart; Nicholas Van As; Margaret R McCredie; Dallas R English; Graham G Giles; John L Hopper; Douglas F Easton
Journal:  Genet Epidemiol       Date:  2011-07-18       Impact factor: 2.135

Review 4.  Overview of mechanisms of cancer chemopreventive agents.

Authors:  Silvio De Flora; Lynnette R Ferguson
Journal:  Mutat Res       Date:  2005-08-16       Impact factor: 2.433

Review 5.  Surviving adult cancers. Part 1: Physiologic effects.

Authors:  L J Loescher; D Welch-McCaffrey; S A Leigh; B Hoffman; F L Meyskens
Journal:  Ann Intern Med       Date:  1989-09-01       Impact factor: 25.391

Review 6.  The adenoma carcinoma sequence in colorectal neoplasia.

Authors:  P B Paty; A M Cohen
Journal:  Gastroenterologist       Date:  1993-12

Review 7.  Survivorship: adult cancer survivors.

Authors:  Patricia A Ganz
Journal:  Prim Care       Date:  2009-12       Impact factor: 2.907

Review 8.  Aspirin and non-steroidal anti-inflammatory drugs for cancer prevention: an international consensus statement.

Authors:  Jack Cuzick; Florian Otto; John A Baron; Powel H Brown; John Burn; Peter Greenwald; Janusz Jankowski; Carlo La Vecchia; Frank Meyskens; Hans Jörg Senn; Michael Thun
Journal:  Lancet Oncol       Date:  2009-05       Impact factor: 41.316

Review 9.  MTHFR 677TT genotype and disease risk: is there a modulating role for B-vitamins?

Authors:  R Reilly; H McNulty; K Pentieva; J J Strain; M Ward
Journal:  Proc Nutr Soc       Date:  2013-10-17       Impact factor: 6.297

Review 10.  Human cancer chemoprevention: hurdles and challenges.

Authors:  Vaqar Mustafa Adhami; Hasan Mukhtar
Journal:  Top Curr Chem       Date:  2013
View more
  43 in total

1.  A Pilot Study of a Grape Seed Procyanidin Extract for Lung Cancer Chemoprevention.

Authors:  Jenny T Mao; Qing-Yi Lu; Bingye Xue; Patricia Neis; Felix D Zamora; Laurie Lundmark; Clifford Qualls; Larry Massie
Journal:  Cancer Prev Res (Phila)       Date:  2019-05-28

Review 2.  Chemoprevention agents for melanoma: A path forward into phase 3 clinical trials.

Authors:  Joanne M Jeter; Tawnya L Bowles; Clara Curiel-Lewandrowski; Susan M Swetter; Fabian V Filipp; Zalfa A Abdel-Malek; Larisa J Geskin; Jerry D Brewer; Jack L Arbiser; Jeffrey E Gershenwald; Emily Y Chu; John M Kirkwood; Neil F Box; Pauline Funchain; David E Fisher; Kari L Kendra; Ashfaq A Marghoob; Suephy C Chen; Michael E Ming; Mark R Albertini; John T Vetto; Kim A Margolin; Sherry L Pagoto; Jennifer L Hay; Douglas Grossman; Darrel L Ellis; Mohammed Kashani-Sabet; Aaron R Mangold; Svetomir N Markovic; Frank L Meyskens; Kelly C Nelson; Jennifer G Powers; June K Robinson; Debjani Sahni; Aleksandar Sekulic; Vernon K Sondak; Maria L Wei; Jonathan S Zager; Robert P Dellavalle; John A Thompson; Martin A Weinstock; Sancy A Leachman; Pamela B Cassidy
Journal:  Cancer       Date:  2018-10-03       Impact factor: 6.860

3.  A Topical Zinc Ionophore Blocks Tumorigenic Progression in UV-exposed SKH-1 High-risk Mouse Skin.

Authors:  Rebecca Justiniano; Jessica Perer; Anh Hua; Mohammad Fazel; Andrea Krajisnik; Christopher M Cabello; Georg T Wondrak
Journal:  Photochem Photobiol       Date:  2017-07-21       Impact factor: 3.421

Review 4.  Natural Forms of Vitamin E as Effective Agents for Cancer Prevention and Therapy.

Authors:  Qing Jiang
Journal:  Adv Nutr       Date:  2017-11-15       Impact factor: 8.701

Review 5.  The dawn of vaccines for cancer prevention.

Authors:  Olivera J Finn
Journal:  Nat Rev Immunol       Date:  2017-12-27       Impact factor: 53.106

6.  Collagen I enhances the efficiency and anti-tumor activity of dendritic-tumor fusion cells.

Authors:  Jian He; Rong Zheng; Zhenghua Zhang; Jie Tan; Chaofan Zhou; Guoqing Zhang; Xinglu Jiang; Qianyi Sun; Sufang Zhou; Duo Zheng; Yong Huang; Lige Wu; Zongqiang Lai; Jieping Li; Nuo Yang; Xiaoling Lu; Yongxiang Zhao
Journal:  Oncoimmunology       Date:  2017-08-08       Impact factor: 8.110

Review 7.  Diabetes Mellitus and Obesity as Risk Factors for Pancreatic Cancer.

Authors:  Guido Eibl; Zobeida Cruz-Monserrate; Murray Korc; Maxim S Petrov; Mark O Goodarzi; William E Fisher; Aida Habtezion; Aurelia Lugea; Stephen J Pandol; Phil A Hart; Dana K Andersen
Journal:  J Acad Nutr Diet       Date:  2017-09-12       Impact factor: 4.910

Review 8.  Integrative analysis of exogenous, endogenous, tumour and immune factors for precision medicine.

Authors:  Shuji Ogino; Jonathan A Nowak; Tsuyoshi Hamada; Amanda I Phipps; Ulrike Peters; Danny A Milner; Edward L Giovannucci; Reiko Nishihara; Marios Giannakis; Wendy S Garrett; Mingyang Song
Journal:  Gut       Date:  2018-02-06       Impact factor: 23.059

9.  Suppressing glucose metabolism with epigallocatechin-3-gallate (EGCG) reduces breast cancer cell growth in preclinical models.

Authors:  Ran Wei; Limin Mao; Ping Xu; Xinghai Zheng; Robert M Hackman; Gerardo G Mackenzie; Yuefei Wang
Journal:  Food Funct       Date:  2018-11-14       Impact factor: 5.396

10.  Transforming Cancer Prevention through Precision Medicine and Immune-oncology.

Authors:  Thomas W Kensler; Avrum Spira; Judy E Garber; Eva Szabo; J Jack Lee; Zigang Dong; Andrew J Dannenberg; William N Hait; Elizabeth Blackburn; Nancy E Davidson; Margaret Foti; Scott M Lippman
Journal:  Cancer Prev Res (Phila)       Date:  2016-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.